Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
International Journal of Cancer Research
  Year: 2007 | Volume: 3 | Issue: 1 | Page No.: 54-73
DOI: 10.3923/ijcr.2007.54.73
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
Insulin like Growth Factor-1 Receptor: An Anticancer Target Waiting for Hit
Vipin Saxena and N.S. Hari Narayana Moorthy

Abstract:
The Insulin like Growth Factor-1 (IGF-1) receptors are members of the super family of Receptor Tyrosine Kinase (RTKs) implicated in human cancers due to amplification, overexpression or somatic mutation of the gene. The type-1 insulin like growth receptors (IGF-1R) is overexpressed by many tumors and mediates proliferation, motility and apoptosis protection. Tumor growth and metastasis can be blocked by agents that inhibit IGF-1R expression or function, suggesting that the IGF-1R is a promising treatment target. The strategies to block IGF-1R function employed anti-IGF-1R antibodies, small-molecule inhibitors of the IGF-1R tyrosine kinase, antisense oligodeoxynucleotides and antisense RNA, small inhibitory RNA, triple helix, dominant negative mutant and various compounds reducing ligand availability. Studies show that antisense IGF-1R expression in melanoma cells leads to enhanced radio sensitivity and impaired activation of ATM, required for DNA double strand break repair. Antisense and dominant negative strategies also enhance tumor cell chemosensitivity induced by tumor cells and killed in vivo by IGF-1R antisense. However, antisense agents cause only modest IGF-1R down regulation and can affect the insulin receptor. Specificity is an important issue for the development of both kinase inhibitors and molecular reagents. Using an array-based screen to identify accessible region of IGF-1R mRNA, are designed small interfering RNAs (siRNAs) that induce potent IGF-1R gene silencing without affecting the insulin receptor. These siRNAs block IGF-signaling, enhancing radio and chemosensitivity and show a genuine therapeutic potential. The clinical efficacy of IGF-1R targeting will be determined by key factors including the role of receptors in established tumors. The potency of inhibition achieved in vivo and the extent to which other signaling pathways compensate for IGF-1R loss.
PDF Fulltext XML References Citation Report Citation
 RELATED ARTICLES:
  •    Lambda Phage Nanoparticles for Targetomics
  •    Molecular Diagnostics and Therapy of Acute Myeloid Leukemia
  •    Growth Hormone Deficiency in Children and Adolescents with Cerebral Palsy: Relation to Gross Motor Function and Degree of Spasticity
  •    A Review of Antisense Therapeutic Interventions for Molecular Biological Targets in Various Diseases
How to cite this article:

Vipin Saxena and N.S. Hari Narayana Moorthy, 2007. Insulin like Growth Factor-1 Receptor: An Anticancer Target Waiting for Hit. International Journal of Cancer Research, 3: 54-73.

DOI: 10.3923/ijcr.2007.54.73

URL: https://scialert.net/abstract/?doi=ijcr.2007.54.73

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 

       

       

Curve Bottom